Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates

BACKGROUND: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831, a clinical candidate for treatment of schizophrenia, is a combination of olanzapine and sa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Psychopharmacol
Egile Nagusiak: Cunningham, Jacobi I, Eyerman, David J, Todtenkopf, Mark S, Dean, Reginald L, Deaver, Daniel R, Sanchez, Connie, Namchuk, Mark
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2019
Gaiak:
Original Papers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6764014/
https://ncbi.nlm.nih.gov/pubmed/31294646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0269881119856850
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak